OncoImmune is a clinical-stage biopharmaceutical company engaged in the discovery and development of biopharmaceuticals for the treatment of cancer and autoimmune disease. Its lead molecule, CD24Fc, suppresses the immune response in animal models of graft-versus-host disease, multiple sclerosis, and rheumatoid arthritis. The company also develops sialidase inhibitors for the treatment of polybacterial sepsis, and other treatments and technologies.